{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:07:39Z","timestamp":1789913259464,"version":"4.0.1"},"reference-count":38,"publisher":"EDP Sciences","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Sci (Paris)"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1051\/medsci\/2008243306","type":"journal-article","created":{"date-parts":[[2011,3,5]],"date-time":"2011-03-05T07:31:51Z","timestamp":1299310311000},"page":"306-313","source":"Crossref","is-referenced-by-count":7,"title":["Les kino\u00efdes"],"prefix":"10.1051","volume":"24","author":[{"given":"Armand","family":"Bensussan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Bizzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Pouletty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Zagury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"250","published-online":{"date-parts":[[2008,3,15]]},"reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Leclerc C. L\u2019apport des nouvelles technologies en vaccinologie.Med Sci (Paris)2007; 23 : 386\u201390.","DOI":"10.1051\/medsci\/2007234386"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Zagury D, Le Buanec H, Bizzini B,et al.Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseases.Cytokine Growth Factor Rev2003; 14 : 123\u201337.","DOI":"10.1016\/S1359-6101(03)00004-2"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Belshe RB, Graham BS, Keefer MC,et al.Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID Aids vaccine clinical trials network.JAMA1994; 272 : 475\u201380.","DOI":"10.1001\/jama.272.6.475"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Bleumer I, Tiemessen DM, Oosterwijk-Wakka JC,et al.Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells.J Immunother2007; 30 : 116\u201322.","DOI":"10.1097\/01.cji.0000211318.22902.ec"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.N Engl J Med2007; 356 : 1915\u201327.","DOI":"10.1056\/NEJMoa061741"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Orenstein JM, Preble OT, Kind P, Schulof R. The relationship of serum alpha-interferon and ultrastructural markers in HIV-seropositive individuals.Ultrastruct Pathol1987; 11 : 673\u20139.","DOI":"10.3109\/01913128709048453"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Badou A, Bennasser Y, Moreau M,et al.Tat protein of human immunodeficiency virus type 1 induces interleukin-10 in human peripheral blood monocytes: implication of protein kinase C-dependent pathway.J Virol2000; 74 : 10551\u201362.","DOI":"10.1128\/JVI.74.22.10551-10562.2000"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Kekow J, Wachsman W, McCutchan JA,et al.Transforming growth factor beta and noncytopathic mechanisms of immunodeficiency in human immunodeficiency virus infection.Proc Natl Acad Sci USA1990; 87 : 8321\u20135.","DOI":"10.1073\/pnas.87.21.8321"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Gallo RC. Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine.Proc Natl Acad Sci USA1999; 96 : 8324\u20136.","DOI":"10.1073\/pnas.96.15.8324"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Le Buanec H, D\u2019Anna R, Lachgar A,et al.HPV-16 E7 but not E6 oncogenic protein triggers both cellular immunosuppression and angiogenic processes.Biomed Pharmacother1999; 53 : 424\u201331.","DOI":"10.1016\/S0753-3322(99)80122-X"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"D\u2019Anna R, Le Buanec H, Alessandri G,et al.Selective activation of cervical microvascular endothelial cells by human papillomavirus 16-e7 oncoprotein.J Natl Cancer Inst2001; 93 : 1843\u201351.","DOI":"10.1093\/jnci\/93.24.1843"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Akagi K, Ikeda Y, Miyazaki M,et al.Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues.Br J Cancer2000; 83 : 887\u201391.","DOI":"10.1054\/bjoc.2000.1396"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Feldmann M, Steinman L. Design of effective immunotherapy for human autoimmunity.Nature2005; 435 : 612\u20139.","DOI":"10.1038\/nature03727"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Le Buanec H, Delavallee L, Bessis N,et al.TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation.Proc Natl Acad Sci USA2006; 103 : 19442\u20137.","DOI":"10.1073\/pnas.0604827103"},{"key":"R15","unstructured":"Bizzini B, Achour A. \u00ab Kinoids \u00bb: the basis for anticytokine immunization and their use in HIV infection.Cell Mol Biol1995; 41 : 351\u20136."},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Sabbatini PJ, Kudryashov V, Ragupathi G,et al.Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial.Int J Cancer2000; 87 : 79\u201385.","DOI":"10.1002\/1097-0215(20000701)87:1<79::AID-IJC12>3.3.CO;2-C"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Lamm DL, Dehaven JI, Riggs DR. Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies.Eur Urol2000; 37 (suppl 3) : 41\u20134.","DOI":"10.1159\/000052391"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Richard M, Grencis RK, Humphreys NE,et al.Anti-IL-9 vaccination prevents worm expulsion and blood eosinophilia in Trichuris muris-infected mice.Proc Natl Acad Sci USA2000; 97 : 767\u201372.","DOI":"10.1073\/pnas.97.2.767"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Uyttenhove C, Van Snick J. Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis.Eur J Immunol2006; 36 : 2868\u201374.","DOI":"10.1002\/eji.200636662"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Chackerian B, Lenz P, Lowy DR, Schiller JT. Determinants of autoantibody induction by conjugated papillomavirus virus-like particles.J Immunol2002; 169 : 6120\u20136.","DOI":"10.4049\/jimmunol.169.11.6120"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Galle P, Hougs L, Barington T,et al.Knocking out IL-6 by vaccination.Eur J Immunol2004; 34 : 291\u2013300.","DOI":"10.1002\/eji.200324338"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Spohn G, Guler R, Johansen P,et al.A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis.J Immunol2007; 178 : 7450\u20137.","DOI":"10.4049\/jimmunol.178.11.7450"},{"key":"R23","unstructured":"Chensue SW, Terebuh PD, Remick DG,et al.In vivobiologic and immunohistochemical analysis of interleukin-1 alpha, beta and tumor necrosis factor during experimental endotoxemia. Kinetics, Kupffer cell expression, and glucocorticoid effects.Am J Pathol1991; 138 : 395\u2013402."},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Weiner GJ. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides.J Leukoc Biol2000; 68 : 455\u201363.","DOI":"10.1189\/jlb.68.4.455"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Gringeri A, Musicco M, Hermans P,et al.Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1 infected patients (the EURIS study). JAcquir Immune Defic Syndr Hum Retrovirol1999; 20 : 358\u201370.","DOI":"10.1097\/00042560-199904010-00006"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Rad FH, Le Buanec H, Paturance S,et al.VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases.Proc Natl Acad Sci USA2007; 104 : 2837\u201342.","DOI":"10.1073\/pnas.0611022104"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Le Buanec H, Paturance S, Couillin I,et al.Control of allergic reactions in mice by an active anti-murine IL-4 immunization.Vaccine2007; 25 : 7206\u201316.","DOI":"10.1016\/j.vaccine.2007.07.029"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Raaberg L, Nexo E, Jorgensen PE,et al.Fetal effects of epidermal growth factor deficiency induced in rats by autoantibodies against epidermal growth factor.Pediatr Res1995; 37 : 175\u201381.","DOI":"10.1203\/00006450-199502000-00009"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Svenson M, Hansen MB, Thomsen AR,et al.Cytokine vaccination: neutralising IL-1alpha autoantibodies induced by immunisation with homologous IL-1alpha.J Immunol Methods2000; 236 : 1\u20138.","DOI":"10.1016\/S0022-1759(99)00232-X"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Gonzalez G, Crombet T, Catala M,et al.A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial.Ann Oncol1998; 9 : 431\u20135.","DOI":"10.1023\/A:1008261031034"},{"key":"R31","doi-asserted-by":"crossref","unstructured":"Elliott MJ, Maini RN, Feldmann M,et al.Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2)versusplacebo in rheumatoid arthritis.Lancet1994; 344 : 1105\u201310.","DOI":"10.1016\/S0140-6736(94)90628-9"},{"key":"R32","unstructured":"Den Broeder A, Van de Putte L, Rau R,et al.A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis.J Rheumatol2002; 29 : 2288\u201398."},{"key":"R33","doi-asserted-by":"crossref","unstructured":"Weinblatt ME, Kremer JM, Bankhurst AD,et al.A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.N Engl J Med1999; 340 : 253\u20139.","DOI":"10.1056\/NEJM199901283400401"},{"key":"R34","doi-asserted-by":"crossref","unstructured":"Kabbinavar F, Hurwitz HI, Fehrenbacher L,et al.Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer.J Clin Oncol2003; 21 : 60\u20135.","DOI":"10.1200\/JCO.2003.10.066"},{"key":"R35","doi-asserted-by":"crossref","unstructured":"Anderson PJ. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles.Semin Arthritis Rheum2005; 34 : 19\u201322.","DOI":"10.1016\/j.semarthrit.2005.01.005"},{"key":"R36","doi-asserted-by":"crossref","unstructured":"Friedberg JW. Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy.Hematology Am Soc Hematol Educ Program2005; 329\u201334.","DOI":"10.1182\/asheducation-2005.1.329"},{"key":"R37","doi-asserted-by":"crossref","unstructured":"Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy.Nat Rev Cancer2004; 4 : 4 23\u201336.","DOI":"10.1038\/nrc1369"},{"key":"R38","doi-asserted-by":"crossref","unstructured":"Silbermann B, Launay O. Pr\u00e9vention des infections \u00e0 papillomavirus et du zona : nouveaux vaccins.Med Sci (Paris)2007; 23 : 423\u20137.","DOI":"10.1051\/medsci\/2007234423"}],"container-title":["m\u00e9decine\/sciences"],"original-title":[],"link":[{"URL":"http:\/\/www.medecinesciences.org\/10.1051\/medsci\/2008243306\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T14:16:41Z","timestamp":1685974601000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.medecinesciences.org\/10.1051\/medsci\/2008243306"}},"subtitle":["Une nouvelle g\u00e9n\u00e9ration de vaccins th\u00e9rapeutiques"],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":38,"journal-issue":{"issue":"3"},"alternative-id":["medsci2008243p306"],"URL":"https:\/\/doi.org\/10.1051\/medsci\/2008243306","relation":{},"ISSN":["0767-0974","1958-5381"],"issn-type":[{"value":"0767-0974","type":"print"},{"value":"1958-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}